Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| PL |
B
|
Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
|
407.5m PLN |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
385B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.8B USD |
Loading...
|
Market Distribution
| Min | -9 940 700% |
| 30th Percentile | -3.7% |
| Median | 2.9% |
| 70th Percentile | 9.1% |
| Max | 196 605.3% |
Other Profitability Ratios
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Glance View
Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 223 full-time employees. The company went IPO on 2011-07-29.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Biomed Lublin Wytwornia Surowic i Szczepionek SA is 14.1%, which is above its 3-year median of 13.1%.
Over the last 3 years, Biomed Lublin Wytwornia Surowic i Szczepionek SA’s Net Margin has increased from 8.6% to 14.1%. During this period, it reached a low of 5.7% on Sep 30, 2020 and a high of 14.1% on May 1, 2023.